NYSE:ATRPackaging
Assessing AptarGroup (ATR) Valuation After New Nasal Vaccine And Eye Care Technology Developments
AptarGroup (ATR) is back in focus after its LuerVax and Spray Divider nasal devices were selected for CastleVax’s Phase II intranasal COVID-19 vaccine trial, along with renewed attention on its Beat the Blink eye care platform.
See our latest analysis for AptarGroup.
Despite the fresh attention on its nasal vaccine and eye care platforms, AptarGroup’s share price has been relatively muted, with a 2.73% 1 month share price return and a 1.77% year to date share price return. The 1 year total...